title: Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients.
abstract: NY-ESO-1 is a cancer/testis antigen expressed in a range of human malignancies, and a number of vaccine strategies targeting NY-ESO-1 are being developed. In the present study, the safety and immunogenicity of recombinant vaccinia-NY-ESO-1 and recombinant fowlpox-NY-ESO-1 were analyzed in a series of 36 patients with a range of different tumor types. Each construct was first tested individually at two different dose levels and then in a prime-boost setting with recombinant vaccinia-NY-ESO-1 followed by recombinant fowlpox-NY-ESO-1. The vaccines were well tolerated either individually or together. NY-ESO-1-specific antibody responses and/or specific CD8 and CD4 T cell responses directed against a broad range of NY-ESO-1 epitopes were induced by a course of at least four vaccinations at monthly intervals in a high proportion of patients. CD8 T cell clones derived from five vaccinated patients were shown to lyse NY-ESO-1-expressing melanoma target cells. In several patients with melanoma, there was a strong impression that the natural course of the disease was favorably influenced by vaccination.
authors.affiliation: Ludwig Institute Clinical Trial Center, Medizinische Klinik II, Hämatologie-Onkologie, Krankenhaus Nordwest, Steinbacher Hohl 2-26, 60488 Frankfurt, Germany. elke.jaeger@licr.org
authors.forename: Elke
authors.initials: E
authors.lastname: Jäger
authors.forename: Julia
authors.initials: J
authors.lastname: Karbach
authors.forename: Sacha
authors.initials: S
authors.lastname: Gnjatic
authors.forename: Antje
authors.initials: A
authors.lastname: Neumann
authors.forename: Armin
authors.initials: A
authors.lastname: Bender
authors.forename: Danila
authors.initials: D
authors.lastname: Valmori
authors.forename: Maha
authors.initials: M
authors.lastname: Ayyoub
authors.forename: Erika
authors.initials: E
authors.lastname: Ritter
authors.forename: Gerd
authors.initials: G
authors.lastname: Ritter
authors.forename: Dirk
authors.initials: D
authors.lastname: Jäger
authors.forename: Dennis
authors.initials: D
authors.lastname: Panicali
authors.forename: Eric
authors.initials: E
authors.lastname: Hoffman
authors.forename: Linda
authors.initials: L
authors.lastname: Pan
authors.forename: Herbert
authors.initials: H
authors.lastname: Oettgen
authors.forename: Lloyd J
authors.initials: LJ
authors.lastname: Old
authors.forename: Alexander
authors.initials: A
authors.lastname: Knuth
mesh_terms: D000906:Antibodies / Q000097:blood; D000917:Antibody Formation / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D019496:Cancer Vaccines / Q000009:adverse effects / Q000235:genetics / Q000276:immunology*; D002999:Clone Cells; D015331:Cohort Studies; D003602:Cytotoxicity, Immunologic / Q000276:immunology; D000939:Epitopes / Q000276:immunology; D005587:Fowlpox virus / Q000378:metabolism; D006801:Humans; D007111:Immunity, Cellular / Q000276:immunology*; D008565:Membrane Proteins / Q000276:immunology; D009363:Neoplasm Proteins / Q000276:immunology*; D009369:Neoplasms / Q000276:immunology*; D010446:Peptide Fragments / Q000276:immunology*; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000009:adverse effects / Q000235:genetics / Q000276:immunology*; D014616:Vaccinia virus / Q000235:genetics
chemical_list: D000906:Antibodies; D019496:Cancer Vaccines; D000939:Epitopes; D008565:Membrane Proteins; D009363:Neoplasm Proteins; D010446:Peptide Fragments; D014614:Vaccines, Synthetic; C504237:peptide NY-ESO-1 157-165